Want to see YARW full AI Analyst Report?
Top Page
Yarrow Bioscience
(NASDAQ:YARW)
Select Model
Select Model
Rating:58Neutral
Price Target:
$43.00
▲(1.20% Upside)
Action:Reiterated
Date:08/03/26
The score is held back primarily by weak financial performance driven by minimal/declining revenue, large ongoing losses, and sustained cash burn. Offsetting this are strong technical uptrend signals and positive corporate developments (merger completion with substantial financing and pipeline milestones). Valuation is mixed due to negative earnings (negative P/E), with only modest support from the dividend yield.
Positive Factors
Low Leverage / No Debt
Practically no debt reduces refinancing and interest-rate risk and gives the company financial flexibility to fund clinical programs. Over 2–6 months this structural strength lowers insolvency risk and preserves optionality for non-dilutive partnerships or staged financings.
Negative Factors
Minimal & Declining Revenue
Very low and falling revenue means no meaningful commercial cash inflows to offset R&D and G&A. Structurally, this forces ongoing reliance on capital markets or partnerships for funding and limits the company’s ability to self-fund development absent clinical or licensing successes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / No Debt
Practically no debt reduces refinancing and interest-rate risk and gives the company financial flexibility to fund clinical programs. Over 2–6 months this structural strength lowers insolvency risk and preserves optionality for non-dilutive partnerships or staged financings.
Read all positive factors
Yarrow Bioscience (YARW) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$113.44M
Dividend Yield42.15%
Average Volume (3M)2.75M
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth1.26%
EPS Growth48.11%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-888.01
Shares Outstanding2,669,746
10 Day Avg. Volume3,707,448
30 Day Avg. Volume2,746,500
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.87
P/FCF Ratio-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$57.00Price Target Upside34.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-76
Revenue Forecast (FY)$350.00K
Yarrow Bioscience Business Overview & Revenue Model
Company Description
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormon...
How the Company Makes Money
As a clinical-stage company, VYNE Therapeutics does not have publicly disclosed, recurring product-sales revenue from commercialized drugs (null). Its cash inflows have primarily been driven by financing activities such as issuing equity and, wher...
Yarrow Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 482.00K | 570.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| Gross Profit | 476.00K | 547.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| EBITDA | -19.25M | -26.73M | -39.80M | -27.87M | -33.86M | -38.04M |
| Net Income | -18.71M | -26.48M | -39.83M | -28.45M | -23.21M | -73.33M |
Balance Sheet | ||||||
| Total Assets | 23.60M | 30.16M | 66.91M | 97.69M | 40.76M | 67.05M |
| Cash, Cash Equivalents and Short-Term Investments | 22.93M | 29.01M | 61.52M | 93.25M | 30.91M | 42.25M |
| Total Debt | 0.00 | 0.00 | 99.00K | 214.00K | 0.00 | 349.00K |
| Total Liabilities | 1.54M | 2.40M | 14.82M | 8.95M | 9.56M | 18.41M |
| Stockholders Equity | 22.06M | 27.77M | 52.09M | 88.73M | 31.20M | 48.64M |
Cash Flow | ||||||
| Free Cash Flow | -16.93M | -33.12M | -34.09M | -25.34M | -29.20M | -56.37M |
| Operating Cash Flow | -16.93M | -33.12M | -33.97M | -25.34M | -29.20M | -56.37M |
| Investing Cash Flow | 17.86M | 37.37M | 23.36M | -57.35M | 15.67M | 1.03M |
| Financing Cash Flow | -51.00K | -143.00K | -141.00K | 82.39M | 1.65M | 39.78M |
Yarrow Bioscience Technical Analysis
42.49
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YARW, the sentiment is undefined. The current price of 42.49 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for YARW.
Yarrow Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $113.44M | -0.05 | -69.57% | 42.68% | 1.26% | 48.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $7.69M | -2.76 | -39.28% | ― | 33.30% | 40.59% | |
45 Neutral | $154.49M | -1.84 | -116.86% | ― | -98.25% | 76.83% | |
44 Neutral | $10.84M | -0.59 | -96.39% | ― | ― | 81.87% | |
41 Neutral | $18.29M | -0.33 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
YARW
Yarrow Bioscience
42.49
32.79
337.86%
KZIA
Kazia Therapeutics
13.52
6.10
82.21%
XBIO
Xenetic Biosciences
3.28
0.34
11.56%
KALA
KALA BIO
0.95
-428.06
-99.78%
INAB
IN8bio
1.10
-1.29
-53.97%
Yarrow Bioscience Corporate Events
Business Operations and Strategy
Yarrow Bioscience Alters Capital Structure With Warrant Exchange
Neutral
Jul 30, 2026
On July 29, 2026, Yarrow Bioscience, Inc. entered into an exchange agreement with an existing stockholder to swap 133,290 shares of common stock for an equal number of pre-funded warrants exercisable at a nominal price of $0.0001 per share. The pr...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesDividendsM&A TransactionsPrivate Placements and FinancingStock Split
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut
Positive
Jul 28, 2026
On July 27, 2026, Yarrow Bioscience closed its merger with VYNE Therapeutics, completed approximately $200 million in pre-closing private financings and began operating under the Yarrow Bioscience name, with shares trading on Nasdaq under the tick...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.